Update From a Global Phase II Study of Lifileucel, an Autologous TIL Therapy, in Patients With Previously Treated Advanced Melanoma

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Updated data continue to show encouraging safety and efficacy of TIL therapy with lifileucel in advanced/metastatic melanoma after progression on prior anti–PD-1/PD-L1 and BRAF ± MEK inhibitors.
Format: Microsoft PowerPoint (.ppt)
File Size: 218 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings